Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruce Feinberg

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Future Oncology (London, England)|March 28, 2025
Second line advanced or metastatic non-small cell lung cancer treatment after chemo-immunotherapy: a retrospective studyLyudmila Bazhenova, Beilei Cai, Danielle Gentile, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2023
Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid LeukemiaAndrew J Klink, Scott J Keating, John Brokars, et al.
The Oncologist|January 18, 2020
Comparative Effectiveness of Palliative Chemotherapy in Metastatic Breast Cancer: A Real-World Evidence AnalysisBruce Feinberg, Jonathan Kish, Igoni Dokubo, et al.
Future Oncology (London, England)|January 15, 2025
Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United StatesTammy A Schuler, Shital Kamble, Kaushal Desai, et al.
The American Journal of Managed Care|May 25, 2023
Better together? costs of first-line chemoimmunotherapy for advanced non-small cell lung cancerJonathan Kish, Djibril Liassou, John Hartman, et al.
Future Oncology (London, England)|August 8, 2020
Making the case for EGFR TKI sequencing in <i>EGFR</i> mutation-positive NSCLC: a GioTag study US patient analysisBruce Feinberg, Balazs Halmos, Rasim Gucalp, et al.
Immunotherapy|June 20, 2020
Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphomaAjeet Gajra, Yolaine Jeune-Smith, Jonathan Kish, et al.
Future Oncology (London, England)|September 21, 2020
Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experimentBruce Feinberg, Skyler Hime, Jeff Wojtynek, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 16, 2011
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapyBruce Feinberg, James Gilmore, Sally Haislip, et al.
Journal of Managed Care & Specialty Pharmacy|April 5, 2019
Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United StatesAndrew J Klink, Bartosz Chmielowski, Bruce Feinberg, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Future Oncology (London, England)|March 28, 2025
Second line advanced or metastatic non-small cell lung cancer treatment after chemo-immunotherapy: a retrospective studyLyudmila Bazhenova, Beilei Cai, Danielle Gentile, et al.
Clinical Lymphoma, Myeloma & Leukemia|December 22, 2023
Real-World Effectiveness of Dasatinib Versus Imatinib in Newly Diagnosed Patients With Chronic Myeloid LeukemiaAndrew J Klink, Scott J Keating, John Brokars, et al.
The Oncologist|January 18, 2020
Comparative Effectiveness of Palliative Chemotherapy in Metastatic Breast Cancer: A Real-World Evidence AnalysisBruce Feinberg, Jonathan Kish, Igoni Dokubo, et al.
Future Oncology (London, England)|January 15, 2025
Prevalence of medical conditions or comorbidities influencing first-line therapy in unresectable hepatocellular carcinoma in the United StatesTammy A Schuler, Shital Kamble, Kaushal Desai, et al.
The American Journal of Managed Care|May 25, 2023
Better together? costs of first-line chemoimmunotherapy for advanced non-small cell lung cancerJonathan Kish, Djibril Liassou, John Hartman, et al.
Future Oncology (London, England)|August 8, 2020
Making the case for EGFR TKI sequencing in <i>EGFR</i> mutation-positive NSCLC: a GioTag study US patient analysisBruce Feinberg, Balazs Halmos, Rasim Gucalp, et al.
Immunotherapy|June 20, 2020
Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphomaAjeet Gajra, Yolaine Jeune-Smith, Jonathan Kish, et al.
Future Oncology (London, England)|September 21, 2020
Physician treatment of metastatic triple-negative breast cancer in the immuno-oncology era: a discrete choice experimentBruce Feinberg, Skyler Hime, Jeff Wojtynek, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|July 16, 2011
Impact of initiating antiemetic prophylaxis with palonosetron versus ondansetron on risk of uncontrolled chemotherapy-induced nausea and vomiting in patients with lung cancer receiving multi-day chemotherapyBruce Feinberg, James Gilmore, Sally Haislip, et al.
Journal of Managed Care & Specialty Pharmacy|April 5, 2019
Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United StatesAndrew J Klink, Bartosz Chmielowski, Bruce Feinberg, et al.
Pageof 5